<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04717791</url>
  </required_header>
  <id_info>
    <org_study_id>RFNV001</org_study_id>
    <nct_id>NCT04717791</nct_id>
  </id_info>
  <brief_title>Evaluate the Effectiveness of the Vivaer ARC Stylus for Nasal Breathing</brief_title>
  <official_title>Low Temperature Controlled Radiofrequency Intranasal Remodeling Treatment of the Nasal Valve Area. A Multicentric Long-term Evaluation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>HNO-Praxis Alte Post</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Aerin Medical</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>HNO-Praxis Alte Post</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Prospective, Multicenter, Non-Randomized Study of the Aerin Medical Vivaer ARC Stylus for&#xD;
      Nasal Airway Obstruction&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective of this post-market study is to continue to evaluate the effectiveness&#xD;
      of the Vivaer® ARC Stylus for treating the nasal valve area to improve symptoms in those&#xD;
      diagnosed with nasal airway obstruction using validated questionaires.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">September 8, 2020</start_date>
  <completion_date type="Anticipated">May 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">March 30, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>response rate Nose Score</measure>
    <time_frame>3 Months, 6, 12 and 24 months</time_frame>
    <description>The primary efficacy endpoint is the responder rate at 3 months after the procedure for the participants.&#xD;
Individual participant success (responder) is defined as at least 1 Nasal Obstruction Symptom Evaluation (NOSE) class improvement or an improvement (decrease) in NOSE score of 20% or more from baseline at the 3-month evaluation.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy measurement using the change in mean NOSE SCORE</measure>
    <time_frame>3 Months, 6, 12 and 24 months</time_frame>
    <description>Efficacy measurement using the change in mean NOSE SCORE from baseline to the 3-month evaluation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety Control regarding</measure>
    <time_frame>3 Months, 6, 12 and 24 months</time_frame>
    <description>Safety Control regarding the frequency of device-related and procedure-related adverse events :</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Adverse events</measure>
    <time_frame>3 Months, 6, 12 and 24 months</time_frame>
    <description>Incidence (type and category) of adverse events overall and by follow-up interval.</description>
  </other_outcome>
  <other_outcome>
    <measure>Nasal Assessment</measure>
    <time_frame>3 Months, 6, 12 and 24 months</time_frame>
    <description>The target nasal valve area within each nostril will be visually assessed at baseline and following the treatment procedure at all evaluations. The use of an endoscope for visual assessment is required. Representative still photographs or video of each nostril will be captured at each visit.</description>
  </other_outcome>
  <other_outcome>
    <measure>Medications</measure>
    <time_frame>3 Months, 6, 12 and 24 months</time_frame>
    <description>Self-reported assessment of an increase, no change, or decrease in medications and/or devices being used for treatment of nasal symptoms at each evaluation compared to use prior to the procedure.</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">115</enrollment>
  <condition>Nasal Obstruction, Bilateral</condition>
  <arm_group>
    <arm_group_label>Procedure</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Subjects will be followed from the Vivaer® treatment date out to 24 months post index procedure.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Vivaer® ARC Stylus</intervention_name>
    <description>The Vivaer procedure will be performed in the study clinic using the VivAer Stylus and Aerin Console. The VivAer Stylus is a disposable handheld device capable of delivering low-temperature bipolar radiofrequency energy to tissue when connected to the Aerin Console radiofrequency generating device. Participants will have both nasal valves treated in a single study procedure session. Each nostril will be treated at up to 3 positions</description>
    <arm_group_label>Procedure</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Eligible subject will meet all the following:&#xD;
&#xD;
          -  1. Age 18 or older 2. Willing and able to provide informed consent 3. Willing and able&#xD;
             to comply with the study protocol 4. Seeking treatment for nasal obstruction 5. NOSE&#xD;
             score of ≥ 60 at Baseline 6. Nasal valve is a primary or significant contributor to&#xD;
             the subject's nasal obstruction as determined by the study investigator (based on&#xD;
             clinical presentation, physical examination, nasal endoscopy, etc.) and the subject&#xD;
             has a positive response to any of the following temporary measures (based on patient&#xD;
             history or office exam):&#xD;
&#xD;
               -  Use of external nasal dilator strips (e.g., Breathe Right Strips)&#xD;
&#xD;
               -  Q-Tip test (manual intranasal lateralization)&#xD;
&#xD;
               -  Use of nasal stents&#xD;
&#xD;
               -  Cottle Maneuver (manual lateral retraction of the cheek)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Eligible subjects will NOT meet any of the following:&#xD;
&#xD;
          1. Prior surgical treatment of the nasal valve&#xD;
&#xD;
          2. Rhinoplasty, septoplasty, inferior turbinate reduction or other surgical nasal&#xD;
             procedures within the past six months&#xD;
&#xD;
          3. Medical conditions which in the opinion of the treating physician would predispose the&#xD;
             subject to poor wound healing or increased surgical risk.&#xD;
&#xD;
          4. Known or suspected to be pregnant or is lactating.&#xD;
&#xD;
          5. Any adjunctive surgical nasal procedure planned on the same day or within 24 months&#xD;
             after the Vivaer procedure.&#xD;
&#xD;
          6. Current participation in any study or participation in any study less than 6 weeks&#xD;
             before study date 1.&#xD;
&#xD;
             -&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>HNO-Praxis</name>
      <address>
        <city>Lichtenfels</city>
        <state>Bayern</state>
        <zip>96215</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HNO-Praxis Alte Post</name>
      <address>
        <city>Göttingen</city>
        <state>Niedersachen</state>
        <zip>37073</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HNO-ZENTRUM am Kudamm</name>
      <address>
        <city>Berlin</city>
        <zip>10629</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>January 17, 2021</study_first_submitted>
  <study_first_submitted_qc>January 20, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 22, 2021</study_first_posted>
  <last_update_submitted>January 20, 2021</last_update_submitted>
  <last_update_submitted_qc>January 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>HNO-Praxis Alte Post</investigator_affiliation>
    <investigator_full_name>Professor Dr. med. Detlef Brehmer</investigator_full_name>
    <investigator_title>PI Prof. Dr. med. Detlef Brehmer</investigator_title>
  </responsible_party>
  <keyword>nasal obstruction</keyword>
  <keyword>nasal valve stenosis</keyword>
  <keyword>nasal valve pathology</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nasal Obstruction</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

